TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06275100

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prehabilitation
Description: Participants will be exposed to exercise and psychoeducation. Aerobic exercise will be on a cycle ergometer tailored to their capability and will aim for a low to moderate intensity.The patients will be exercised using the intermittent protocol of alternating 1 minute moderate and 1 minute low intensity aerobic exercise. This duration can be gradually increased during subsequent sessions depending on the patient's ability. Aerobic exercise will be conducted 2- 3 times per week depending on patient's ability.~In addition, participants are expected to do strength and inspiratory muscle training in their own time.~The psychoeducation booklet and audio are designed with input from in-house clinical psychologist. The aim of the booklet is to explain the emotions they may feel whilst being in hospital, symptoms of anxiety, suggest how to manage anxiety, behavioural strategies that may help and signposting if they require further support.
Study: NCT06535087

Intervention type: DRUG
Intervention: Subcutaneous immunotherapy / Standard Treatment for Asthma and Rhinitis
Description: 1. Subcutaneous Allergen-Specific Immunotherapy:~   * Pre-treatment: Omalizumab subcutaneous injection, with the total IgE level serving as the basis for calculating the dosage for children. The appropriate dosage of omalizumab (each dose ranging from 75 to 600 mg) and administration frequency (once every 4 weeks) are determined based on the baseline IgE (IU/mL, measured before the start of treatment) and body weight (kg).~  * Mite Allergen Preparation: (Antergen/Alutard)~2. Standard Treatment:~   * Asthma: Inhaled corticosteroids (ICS) combined with long-acting beta-2 agonists, leukotriene receptor antagonists.~  * Allergic Rhinitis: Oral antihistamines, nasal antihistamines, nasal corticosteroids, anti-leukotriene drugs, cromolyn sodium, decongestants (oxymetazoline hydrochloride), and nasal saline irrigation.
Study: NCT06110546

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methadone group
Description: Participants will be started on Methadone 5mg, 10mg or 15mg every 8 hours depending on Fentanyl drip rate (0-100mcg/hr, 100-200mcg/hr or \>200mcg/hr) or hydromorphone drip rate (0-1.5mg/hr, 1.5-3mg/hr, or \>3mg/hr).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Participants will receive usual care with IV Fentanyl or hydromorphone per hospital protocols
Study: NCT05882851

Intervention type: BEHAVIORAL
Intervention: determination of the current nutritional status of patients
Description: No intervention was made on the patients. Nutritional status was recorded during the treatment process. Current nutritional status and other risk factors were compared according to recovery status after treatment.

Intervention type: BEHAVIORAL
Intervention: determination of the current nutritional status of patients
Description: No intervention was made on the patients. Nutritional status was recorded during the treatment process. Current nutritional status and other risk factors were compared according to recovery status after treatment.
Study: NCT06283849

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: strategies to break up SB
Description: Participants will be asked to implement strategies to break up their SB every hour for at least 8 hours a day for one week. Strategies will be developed through collaboration with participants during the first study interview and may include (but are not limited to): calf raises, brief (\~5 min) self-paced walking), squats, sit to stand, etc. Participants will wear an activity monitor for assessment of SB and walking. This device (activPAL, PALTechnologies, Glasgow, Scotland) is not an investigational device; it is used for monitoring sedentary behavior.
Study: NCT05794867

Intervention type: DIAGNOSTIC_TEST
Intervention: clinical weaning criteria
Description: Xray chest and calculation of thr rapid shallow breathing rate
Study: NCT05453474

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Whole genome amplification
Description: DNA is amplified by whole genome amplification
Study: NCT06001814

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: One-Mind One-Heart
Description: One-Mind One-Heart will include mindfulness and behavior change skills to address psychological distress, physical activity, diet, and substance use.
Study: NCT06663774

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Physical Fitness Tests
Description: Ippon Reactive Agility Test (IRAT), Y-Balance Test, Upper-Quarter Y Balance Test, Flamingo Balance Test, Flamingo Balance Test, Standing Long Jump Test, 20m Sprint Test, Hand Grip Test, T-Agility Test, Nelson Hand Reaction Test, Judo Specific Fitness Test
Study: NCT06663748

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARX788
Description: 2.2 mg/kg IV infusion on Day 1 of each 42-day treatment cycle.
Study: NCT05923060

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical Aminolevulinate
Description: Topical Levulan Kerastick is applied to actinic keratoses.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT)
Description: PDT is a technique that combines a photosensitizing drug and an intense light source to kill tumor cells.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Red light illumination
Description: To occur post-PTD; used for activation of ALA during photodynamic therapy.
Study: NCT05195996

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propranolol
Description: intravenous propranolol for case patients

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: intravenous saline for placebo
Study: NCT05199948

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Soybean Oil Foods
Description: Three food product containing 10g of soybean oil each will be consumed each day for a today of 30g of soybean oil consumed each day

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Palm Oil Foods
Description: Three food product containing 10g of palm oil each will be consumed each day for a today of 30g of palm oil consumed each day
Study: NCT06001814

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Education
Description: Education will be provided on behavioral cardiovascular disease risk reduction strategies, such as increasing physical activity, reducing salt intake in diet, and reduce/stop alcohol and tobacco-use.
Study: NCT05596318

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Digital CBT-I
Description: The digital CBT-I program is called Sleepio (Big Health, Ltd). Digital CBT-I will be delivered by an animated therapist in six weekly sessions that are approximately 10-20 minutes each. Sessions can be accessed via website or app at a time that is convenient for the participant. Session content is based on standard, in-person CBT-I protocols, and includes sleep restriction, stimulus control, cognitive therapy, relaxation techniques, and sleep hygiene education. The program is interactive, automated, and tailored to participant progress. Additionally, participants will receive supplemental CBT-I content tailored for prenatal and postpartum insomnia.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Digital SHE
Description: The digital SHE program was created by Big Health, Ltd and has a total of six sessions. The content for SHE includes education about sleep stages, sleep architecture, sleep cycles; education about importance of sleep for performance, mood, and health; recommendations for developing healthy sleep habits; recommendations for lifestyle factors that impact sleep; recommendations for creating a sleep-friendly bedroom.
Study: NCT05343793

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NIATx-External Facilitation (NIATx-EF)
Description: For 9-months, organizations in the NIATx-EF study arm will work with one of 4 experienced consultant NIATx External Facilitators (EFs). The EF meets with clinic staff to plan change projects, review ongoing change efforts, discuss successes, and offer guidance on planning future change projects using PDSA cycles. The EF makes a 1-day site visit during the 1st quarter of the implementation period and leads monthly 1-hour phone calls.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NIATx-External Facilitation (NIATx-EF)
Description: For 9-months, organizations in the NIATx-EF study arm will work with one of 4 experienced consultant NIATx External Facilitators (EFs). The EF meets with clinic staff to plan change projects, review ongoing change efforts, discuss successes, and offer guidance on planning future change projects using PDSA cycles. The EF makes a 1-day site visit during the 1st quarter of the implementation period and leads monthly 1-hour phone calls.
Study: NCT06048718

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab-Deruxtecan (T-DXd)
Description: Trastuzumab-deruxtecan is a human HER2-directed antibody-drug conjugate (ADC) composed of humanized anti-HER2 immunoglobulin G1 (IgG1) monoclonal antibody (mAb) with the same amino acid sequence as trastuzumab, covalently linked to the membrane-permeable topoisomerase I inhibitor payload, DXd, an exatecan derivative, via a stable tetrapeptide-based linker, selectively cleaved within tumor cells.
Study: NCT06201598

Intervention type: DEVICE
Intervention: Group 1 - Intervention 1
Description: Endovascular treatment of cerebral aneurysms through the implantation of p64MW HPC and p48MW HPC devices.
Study: NCT05643027

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Acceptance and Commitment Therapy
Description: Six-session, skills-based behavioral intervention targeting risk factors for opioid use disorder in the context of cancer
Study: NCT05875064

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Restoration with resin composite and polyvinyl crown
Description: Restorative treatment of anterior primary teeth with monochromatic composite resin in single insertion through polyvinyl crowns, after selective removal of carious tissue compared to the effectiveness of conventional restoration.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Restoration with conventional resin composite
Description: Restorative treatment of anterior primary teeth with conventional composite resin, after selective removal of carious tissue
Study: NCT05455411

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group-based Parent-implemented Training
Description: A group-based social communication training for parents of preschoolers with autism spectrum disorder will be taught by a speech therapist online (approximately 25 hours distributed over 6 months), with up to 8 parents in a group.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Individual-based Parent-implemented Training
Description: An individual-based social communication training for parents of preschoolers with autism spectrum disorder will be taught by a speech therapist online in a one-on-one format (approximately 25 hours distributed over 6 months).
Study: NCT06354764

Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study: NCT06336538

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MBCT
Description: Mindfulness-Based Cognitive Therapy (MBCT) is a group-based psychological intervention for depression that combines mindfulness training with cognitive therapy.
Study: NCT06409845

Intervention type: DRUG
Intervention: Eptinezumab 100 or 300 mg ev
Description: Patients administered eptinezumab 100 or 300 mg ev quarterly for migraine prevention

Intervention type: DRUG
Intervention: Eptinezumab 100 or 300 mg ev
Description: Patients administered eptinezumab 100 or 300 mg ev quarterly for migraine prevention
Study: NCT05875402

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chimeric antigen receptor T cell preparation targeting GCC
Description: Chimeric antigen receptor T cell preparation targeting GCC
Study: NCT05899777

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yizhi Baduanjin
Description: Yizhi Baduanjin is a newly compiled routine developed on the foundation of the traditional Baduanjin, aiming at the mental and cerebral health of middle-aged and elderly population, which combining the preliminary research result and principles of the traditional routine. It could be practiced in long term to prevent MCI and AD, or simply as a general health exercise for elders.
Study: NCT05630573

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TNM001
Description: intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TNM001
Description: intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TNM001
Description: intramuscular injection

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: intramuscular injection
Study: NCT05713916

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention: Population Health Coordinator
Description: After being notified of the finding of LVH in their patient, the population health coordinator will offer to schedule a dedicated visit for the provider and their patient to discuss this finding through a structured correspondence. Additionally, the population health coordinator will offer to coordinate 24-hour ambulatory blood pressure monitoring before or after the patient visit as part of the evaluation of LVH. Finally, for patients without established cardiovascular care and whose etiology of LVH remains undetermined, the population health coordinator will offer to coordinate a visit with a cardiologist to discuss the finding of LVH.
Study: NCT05748483

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atogepant
Description: Oral Tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atogepant
Description: Oral Tablet
Study: NCT06071910

Intervention type: DEVICE
Group type: OTHER
Intervention: ER-REBOA catheter
Description: To achieve rapid aortic occlusion
Study: NCT05928065

Intervention type: OTHER
Intervention: Collection of datas
Description: Collection of datas: datas of physical examination (swelling, hematoma, edema), benign trauma (non deforming and closed fractures), ultrasound and radiographic images and evaluation of pain.
Study: NCT06576973

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adbelimumab, Albumin paclitaxel, Carboplatin, Apatinib
Description: Adbelimumab 1200mg Day 1; Albumin paclitaxel 260mg/m2, Day 1; carboplatin AUC=5, Day 1; Apatinib 250mg Po Day 2-4. Preoperative neoadjuvant therapy for 4 cycles, one cycle every 21 days.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Esophagectomy
Description: Prior to each surgical procedure, the department engaged in comprehensive discussions and deliberations to ascertain and establish the most suitable course of action. Minimally invasive IvorLewis (intrathoracic anastomosis) or McKeown (neck anastomosis) esophagectomy, including two field extensive lymphadenectomies, was performed according to the tumor location. The resection length should be at least 5cm from the tumor origin according to prechemotherapy by endoscopy. The surgeries will be performed by surgeons with rich experience. Minimally invasive esophagectomy, can be performed using the da Vinci surgical robot, thoracoscope, or laparoscope, or by using an open approach, as judged appropriate by the surgeon.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Collecting samples from participant
Description: Blood, Tumour will be Collected from participant. Fate of sample is Destruction after use. 20 ml of peripheral blood was collected the day before each of the immunotherapy sessions and after surgery. Tumour sample will be collected before neoadjuvant therapy and after surgery.
Study: NCT05377463

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer support to promote uptake and persistence of medication assisted treatment (MAT)
Description: Participants will be assigned to receive peer support to promote uptake of MAT and persistence. This component will consist of two informational sessions, a tailored recovery plan, and on-going support from a peer for the first 6 months.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer support to promote uptake and persistence of medication assisted treatment (MAT)
Description: Participants will be assigned to receive peer support to promote uptake of MAT and persistence. This component will consist of two informational sessions, a tailored recovery plan, and on-going support from a peer for the first 6 months.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Activation Treatment (BAT) to reduce depression
Description: Participants will be assigned to receive BAT treatment for depression. This component will consist of 8 sessions where participants will identify short and long-term goals, values, and the activities unrelated to substance use that were previously enjoyed or are likely to increase a feeling of well-being. This intervention component focuses on making a plan to troubleshoot barriers to re-engage in these activities. Sessions are delivered weekly. The content includes psycho-education about what depression is, the intervention rationale, and the activities and monitoring of activities, building social contracts to engage networks, and discussion of potential barriers to following through with activities.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Activation Treatment (BAT) to reduce depression
Description: Participants will be assigned to receive BAT treatment for depression. This component will consist of 8 sessions where participants will identify short and long-term goals, values, and the activities unrelated to substance use that were previously enjoyed or are likely to increase a feeling of well-being. This intervention component focuses on making a plan to troubleshoot barriers to re-engage in these activities. Sessions are delivered weekly. The content includes psycho-education about what depression is, the intervention rationale, and the activities and monitoring of activities, building social contracts to engage networks, and discussion of potential barriers to following through with activities.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: No Intervention Components
Description: Participants not assigned to components 1 and 2
Study: NCT04421131

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pocket colposcope/Mobile phone camera
Description: The Pocket colposcope or mobile phone camera will be used to capture magnified digital images of the cervix

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mIVAA
Description: A mobile-phone-based telemedicine platform that enables remote consultation with an expert colposcopist
Study: NCT05063422

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: polymyxin b/trimethoprim ophthalmic, Carboxymethyl cellulose
Description: 3 forms of denture adhesives from each brands are used to compare the retentive strength on highly resorbed ridges

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: polymyxin b/trimethoprim ophthalmic, Carboxymethyl cellulose
Description: 3 forms of denture adhesives from each brands are used to compare the retentive strength on highly resorbed ridges

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: polymyxin b/trimethoprim ophthalmic, Carboxymethyl cellulose
Description: 3 forms of denture adhesives from each brands are used to compare the retentive strength on highly resorbed ridges
Study: NCT04773340

Intervention type: BEHAVIORAL
Intervention: Dialectical Behavior Therapy
Description: Behaviorally-focused intervention for individuals with personality disorder and a history of significant behavioral problems.
Study: NCT05660525

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4 weeks of Nicotine lozenge
Description: All participants will receive at least 4 weeks of the NRT Patch. Some will be randomized to receive 4 weeks of lozenge in addition to the NRT Patch. NRT temporarily replaces nicotine from tobacco to reduce motivation to consume tobacco and nicotine withdrawal symptoms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4 weeks of Nicotine lozenge
Description: All participants will receive at least 4 weeks of the NRT Patch. Some will be randomized to receive 4 weeks of lozenge in addition to the NRT Patch. NRT temporarily replaces nicotine from tobacco to reduce motivation to consume tobacco and nicotine withdrawal symptoms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4 weeks of Nicotine lozenge
Description: All participants will receive at least 4 weeks of the NRT Patch. Some will be randomized to receive 4 weeks of lozenge in addition to the NRT Patch. NRT temporarily replaces nicotine from tobacco to reduce motivation to consume tobacco and nicotine withdrawal symptoms.
Study: NCT05748483

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo for Atogepant
Description: Oral Tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topiramate
Description: Oral Capsule
Study: NCT05660525

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4 weeks of Nicotine lozenge
Description: All participants will receive at least 4 weeks of the NRT Patch. Some will be randomized to receive 4 weeks of lozenge in addition to the NRT Patch. NRT temporarily replaces nicotine from tobacco to reduce motivation to consume tobacco and nicotine withdrawal symptoms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4 weeks of Nicotine lozenge
Description: All participants will receive at least 4 weeks of the NRT Patch. Some will be randomized to receive 4 weeks of lozenge in addition to the NRT Patch. NRT temporarily replaces nicotine from tobacco to reduce motivation to consume tobacco and nicotine withdrawal symptoms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4 weeks of Nicotine lozenge
Description: All participants will receive at least 4 weeks of the NRT Patch. Some will be randomized to receive 4 weeks of lozenge in addition to the NRT Patch. NRT temporarily replaces nicotine from tobacco to reduce motivation to consume tobacco and nicotine withdrawal symptoms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4 weeks of Nicotine lozenge
Description: All participants will receive at least 4 weeks of the NRT Patch. Some will be randomized to receive 4 weeks of lozenge in addition to the NRT Patch. NRT temporarily replaces nicotine from tobacco to reduce motivation to consume tobacco and nicotine withdrawal symptoms.
Study: NCT05748483

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Topiramate
Description: Oral Capsule
Study: NCT05968664

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spinal Cord Stimulator
Description: Spinal Cord Stimulator modified to deliver Time Variant Pulse (TVP) stimulation.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Spinal Cord Stimulator
Description: Spinal Cord Stimulator to deliver standard of care Time Invariant Pulse (TIP) stimulation.
Study: NCT06188689

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Pacing
Description: 1. Ventricular 10 beat burst at 500ms (120bpm)~2. Ventricular 10 beat burst at 400ms (150bpm)~3. Atrial 10 beat burst at 500ms (120bpm)~4. Atrial 10 beat burst at 400ms (150bpm).